Trial Profile
Safety and efficacy of daclatasvir plus sofosbuvir in patients with hepatitis C virus infection with genotype 3
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 24 Feb 2017
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary) ; Sofosbuvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 24 Feb 2017 New trial record